AXSM Axsome Therapeutics Inc.

3.01
-0.06  -2%
Previous Close 3.07
Open 3.01
Price To Book 150.5
Market Cap 89737636
Shares 29,813,168
Volume 253,710
Short Ratio
Av. Daily Volume 321,689

SEC filingsSee all SEC filings

  1. 8-K - Current report 181224852
  2. 8-K - Current report 181202452
  3. 8-K - Current report 181180394
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173529
  5. 8-K - Current report 181173356

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 1Q 2019.
AXS-05
Smoking cessation
Phase 2/3 interim analysis December 10, 2018 noted DSMB recommendation to continue trial. Interim effiacy analysis due 2019 with top-line data due 2H 2019 – 1H 2020.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 final data due 1Q 2019.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 trial planned for 4Q 2018 or 1Q 2019.
AXS-07
Migraine
Phase 2 data due early January 2019.
AXS-05 ASCEND
Major Depressive Disorder
Phase 2 trial to be initiated 4Q 2018 with data due 1H 2019.
AXS-12
Narcolepsy

Latest News

  1. Today's Research Reports on Trending Tickers: Axsome Therapeutics and Avid Bioservices
  2. UPDATE: Axsome Therapeutics shares soar 24% premarket on positive trial of Alzheimer's therapy
  3. Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
  4. Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
  5. Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference
  6. Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
  7. Axsome: 3Q Earnings Snapshot
  8. Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
  9. Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy
  10. Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy
  11. Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy
  12. Axsome Therapeutics to Present at Upcoming Investor Conferences
  13. Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets
  14. Axsome Therapeutics Announces $8.9 Million Registered Direct Offering
  15. What Does Axsome Therapeutics Inc’s (NASDAQ:AXSM) Ownership Structure Look Like?
  16. Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation

SEC Filings

  1. 8-K - Current report 181224852
  2. 8-K - Current report 181202452
  3. 8-K - Current report 181180394
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173529
  5. 8-K - Current report 181173356
  6. 8-K - Current report 181171316
  7. 8-K - Current report 181125426
  8. 8-K - Current report 181125402
  9. 8-K - Current report 181123525
  10. 8-K - Current report 181117263